State Street’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

State Street’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-215,507	Closed	-$28.4M	–	4012
2020 Q4	$28.4M	Buy	215,507 +2,438	+1%	+$215K	﹤0.01%	2015
2020 Q3	$10.8M	Sell	213,069 -9,867	-4%	-$444K	﹤0.01%	2404
2020 Q2	$10.6M	Buy	222,936 +5,491	+3%	+$255K	﹤0.01%	2386
2020 Q1	$10.7M	Buy	217,445 +667	+0.3%	+$34K	﹤0.01%	2243
2019 Q4	$12.4M	Sell	216,778 -1,542	-0.7%	-$76.3K	﹤0.01%	2420
2019 Q3	$7.85M	Buy	218,320 +1,523	+0.7%	+$59.5K	﹤0.01%	2585
2019 Q2	$6.74M	Buy	216,797 +11,434	+6%	+$310K	﹤0.01%	2674
2019 Q1	$4.82M	Buy	205,363 +132,216	+181%	+$2.12M	﹤0.01%	2763
2018 Q4	$1.01M	Buy	73,147 +46,547	+175%	+$587K	﹤0.01%	3327
2018 Q3	$266K	Buy	+26,600	New	+$437K	﹤0.01%	3557

State Street's EIDX Position: Q1 2021 in Review

State Street sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 215,507 shares — an estimated $28.4M sold.

State Street first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $28.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

State Street reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
State Street sold 215,507 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $28.4M.
State Street first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
State Street's Eidos Therapeutics, Inc. Common Stock position peaked at $28.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on State Street's 13F filing for Q1 2021, filed 17 May 2021.